The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health ... inflated insulin list prices, ...

The FTC may also recommend suing insulin manufacturers ... U.S. health companies that negotiate insulin prices, arguing the ...

An FTC official said the case argues that PBMs ... a report refuting arguments that the industry raises costs. The drug middlemen say they’re a necessary counterweight to the unchecked ...

endangering patients,” said the FTC's Chair, Lina Khan. “Our inquiry requests information on the factors driving these shortages and scrutinises the practices of opaque drug middlemen.” ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

Elizabeth Warren seeks scrutiny of deals that would allow drug middlemen McKesson, Cardinal Health, and Cencora to also ...

Analyst reactions to Donald Trump’s election victory were mixed Wednesday, with potential positives including an FTC that is ...

The owner of one of the three largest pharmacy middlemen in the United States last month filed suit to quash an attempt by the Federal Trade Commission to investigate industry ...

These prices have been exacerbated by pharmacy benefit managers, or PBMs, middlemen between drug manufacturers ... Scripts over their alleged role in incentivizing higher drug prices. The FTC believes ...

The drug middlemen say they’re a necessary counterweight to the unchecked power of pharmaceutical companies to set prices. The insulin market is dominated by three manufacturers: Eli Lilly & Co., ...